Critical Reanalysis of the Mechanisms Underlying the Cardiorenal Benefits of SGLT2 Inhibitors and Reaffirmation of the Nutrient Deprivation Signaling/Autophagy Hypothesis
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Critical Reanalysis of the Mechanisms Underlying the Cardiorenal Benefits of SGLT2 Inhibitors and Reaffirmation of the Nutrient Deprivation Signaling/Autophagy Hypothesis
Authors
Keywords
-
Journal
CIRCULATION
Volume 146, Issue 18, Pages 1383-1405
Publisher
Ovid Technologies (Wolters Kluwer Health)
Online
2022-11-01
DOI
10.1161/circulationaha.122.061732
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Ulk1-dependent alternative mitophagy plays a protective role during pressure overload in the heart
- (2022) Jihoon Nah et al. CARDIOVASCULAR RESEARCH
- Angiotensin–neprilysin inhibition and renal outcomes across the spectrum of ejection fraction in heart failure
- (2022) Finnian R. Mc Causland et al. EUROPEAN JOURNAL OF HEART FAILURE
- Empagliflozin Enhances Autophagy, Mitochondrial Biogenesis, and Antioxidant Defense and Ameliorates Renal Ischemia/Reperfusion in Nondiabetic Rats
- (2022) Moein Ala et al. Oxidative Medicine and Cellular Longevity
- Renal mTORC1 activation is associated with disease activity and prognosis in lupus nephritis
- (2022) Zhaomin Mao et al. RHEUMATOLOGY
- Sympathetic Denervation Ameliorates Renal Fibrosis via Inhibition of Cellular Senescence
- (2022) Qian Li et al. Frontiers in Immunology
- Canagliflozin protects against cisplatin-induced acute kidney injury by AMPK-mediated autophagy in renal proximal tubular cells
- (2022) Cheol Ho Park et al. Cell Death Discovery
- Sodium-Glucose Co-transporter-2 Inhibitor of Dapagliflozin Attenuates Myocardial Ischemia/Reperfusion Injury by Limiting NLRP3 Inflammasome Activation and Modulating Autophagy
- (2022) Yong-Wei Yu et al. Frontiers in Cardiovascular Medicine
- Chaperone Mediated Autophagy Protects Cardiomyocytes Against Hypoxic-Cell Death
- (2022) Rajeshwary Ghosh et al. AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY
- Acetylation in the regulation of autophagy
- (2022) Yinfeng Xu et al. Autophagy
- Initial Decline ("dip") in Estimated Glomerular Filtration Rate Following Initiation of Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction: Insights from DAPA-HF.
- (2022) Carly Adamson et al. CIRCULATION
- Mitochondrial Sirtuin-3 (SIRT3) Prevents Doxorubicin-Induced Dilated Cardiomyopathy by Modulating Protein Acetylation and Oxidative Stress
- (2022) Mateusz M. Tomczyk et al. Circulation-Heart Failure
- Dapagliflozin attenuates high glucose‐induced endothelial cell apoptosis and inflammation through AMPK / SIRT1 activation
- (2022) Yousef Faridvand et al. CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY
- The SGLT2 Inhibitor Dapagliflozin Increases the Oxidation of Ingested Fatty Acids to Ketones in Type 2 Diabetes
- (2022) Roselle A. Herring et al. DIABETES CARE
- Luseogliflozin inhibits high glucose-induced TGF-β2 expression in mouse cardiomyocytes by suppressing NHE-1 activity
- (2022) Naoya Osaka et al. JOURNAL OF INTERNATIONAL MEDICAL RESEARCH
- Impact of Autophagy on Prognosis of Patients With Dilated Cardiomyopathy
- (2022) Hiromitsu Kanamori et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Empagliflozin Ameliorates Preeclampsia and Reduces Postpartum Susceptibility to Adriamycin in a Mouse Model Induced by Angiotensin Receptor Agonistic Autoantibodies
- (2022) Ruonan Zhai et al. Frontiers in Pharmacology
- An Effective Sodium-Dependent Glucose Transporter 2 Inhibition, Canagliflozin, Prevents Development of Hypertensive Heart Failure in Dahl Salt-Sensitive Rats
- (2022) Lili He et al. Frontiers in Pharmacology
- Hemoglobin Mass and Blood Volume in Patients With Altitude-Related Polycythemia
- (2022) Walter F. J. Schmidt et al. Frontiers in Physiology
- Downregulation of autophagy-related circular RNA (ACR) is correlated with poor survival of patients with chronic heart failure
- (2022) Haihui Yan et al. Bioengineered
- Empagliflozin attenuates cardiac microvascular ischemia/reperfusion through activating the AMPKα1/ULK1/FUNDC1/mitophagy pathway
- (2022) Chen Cai et al. Redox Biology
- 3-Hydroxybutyrate Ameliorates the Progression of Diabetic Nephropathy
- (2022) Jeeyoun Jung et al. Antioxidants
- Direct Cardiac Actions of Sodium-Glucose Cotransporter 2 Inhibition Improve Mitochondrial Function and Attenuate Oxidative Stress in Pressure Overload-Induced Heart Failure
- (2022) Xuan Li et al. Frontiers in Cardiovascular Medicine
- The Adaptive Renal Response for Volume Homeostasis During 2 Weeks of Dapagliflozin Treatment in People With Type 2 Diabetes and Preserved Renal Function on a Sodium-Controlled Diet
- (2022) Rosalie A. Scholtes et al. Kidney International Reports
- Dapagliflozin improves endothelial cell dysfunction by regulating mitochondrial production via the SIRT1/PGC-1α pathway in obese mice
- (2022) Lianqi He et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- The sodium‐glucose co‐transporter‐2 inhibitor ertugliflozin modifies the signature of cardiac substrate metabolism and reduces cardiac mTOR signalling, endoplasmic reticulum stress and apoptosis
- (2022) Julia Moellmann et al. DIABETES OBESITY & METABOLISM
- Effects of Steroidal Mineralocorticoid Receptor Antagonists on Acute and Chronic Estimated Glomerular Filtration Rate Slopes in Patients with Chronic Heart Failure
- (2022) Muthiah Vaduganathan et al. EUROPEAN JOURNAL OF HEART FAILURE
- Effect of empagliflozin on circulating proteomics in heart failure: mechanistic insights into the EMPEROR programme
- (2022) Faiez Zannad et al. EUROPEAN HEART JOURNAL
- SGLT2 Inhibition by Canagliflozin Ameliorates Diet‐induced Obesity by Promoting Intra‐adipose Sympathetic innervation
- (2021) Xuping Yang et al. BRITISH JOURNAL OF PHARMACOLOGY
- Empagliflozin Attenuates Non-Alcoholic Fatty Liver Disease (NAFLD) in High Fat Diet Fed ApoE(-/-) Mice by Activating Autophagy and Reducing ER Stress and Apoptosis
- (2021) Narjes Nasiri-Ansari et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Empagliflozin Regulates the AdipoR1/p-AMPK/p-ACC Pathway to Alleviate Lipid Deposition in Diabetic Nephropathy
- (2021) Zhiqin Zhang et al. Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
- PGC-1α alleviates mitochondrial dysfunction via TFEB-mediated autophagy in cisplatin-induced acute kidney injury
- (2021) Longhui Yuan et al. Aging-US
- Effect of empagliflozin on ectopic fat stores and myocardial energetics in type 2 diabetes: the EMPACEF study
- (2021) B. Gaborit et al. Cardiovascular Diabetology
- Activation of autophagy and suppression of apoptosis by dapagliflozin attenuates experimental inflammatory bowel disease in rats: Targeting AMPK/mTOR, HMGB1/RAGE and Nrf2/HO-1 pathways
- (2021) Hany H. Arab et al. CHEMICO-BIOLOGICAL INTERACTIONS
- Empagliflozin Effects on Pulmonary Artery Pressure in Patients with Heart Failure: Results from EMpagliflozin Evaluation By MeasuRing ImpAct on HemodynamiCs in PatiEnts with Heart Failure (EMBRACE-HF) Trial
- (2021) Michael E. Nassif et al. CIRCULATION
- Empagliflozin alleviates ethanol‐induced cardiomyocyte injury through inhibition of mitochondrial apoptosis via a SIRT1/PTEN/Akt pathway
- (2021) Ge Tian et al. CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY
- Empagliflozin prevents from early cardiac injury post myocardial infarction in non-diabetic mice
- (2021) Yihai Liu et al. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
- Dapagliflozin ameliorates pancreatic injury and activates kidney autophagy by modulating the AMPK/mTOR signaling pathway in obese rats
- (2021) Krit Jaikumkao et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Dapagliflozin attenuates hypoxia/reoxygenation-caused cardiac dysfunction and oxidative damage through modulation of AMPK
- (2021) Kun-Ling Tsai et al. Cell and Bioscience
- Direct Cardiac Actions of the Sodium Glucose Co‐Transporter 2 Inhibitor Empagliflozin Improve Myocardial Oxidative Phosphorylation and Attenuate Pressure‐Overload Heart Failure
- (2021) Xuan Li et al. Journal of the American Heart Association
- Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists
- (2021) Li Shen et al. JACC-Heart Failure
- The role of autophagy in cardiovascular pathology
- (2021) Damián Gatica et al. CARDIOVASCULAR RESEARCH
- The Cardiac Late Sodium Channel Current is a Molecular Target for the Sodium-Glucose Co-Transporter 2 Inhibitor Empagliflozin
- (2021) Koenraad Philippaert et al. CIRCULATION
- The SGLT2 inhibitor empagliflozin negatively regulates IL-17/IL-23 axis-mediated inflammatory responses in T2DM with NAFLD via the AMPK/mTOR/autophagy pathway
- (2021) Ziyu Meng et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload
- (2021) Milton Packer et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Empagliflozin Inhibits Proximal Tubule NHE3 Activity, Preserves GFR, and Restores Euvolemia in Nondiabetic Rats with Induced Heart Failure
- (2021) Flávio A. Borges-Júnior et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- SIRT6‑specific inhibitor OSS‑128167 exacerbates diabetic cardiomyopathy by aggravating inflammation and oxidative stress
- (2021) Yibo Huang et al. Molecular Medicine Reports
- Sodium–Glucose CoTransporter-2 Inhibitor Empagliflozin Ameliorates Sunitinib-Induced Cardiac Dysfunction via Regulation of AMPK–mTOR Signaling Pathway–Mediated Autophagy
- (2021) Changzhen Ren et al. Frontiers in Pharmacology
- Dapagliflozin Alleviates Hepatic Steatosis by Restoring Autophagy via the AMPK-mTOR Pathway
- (2021) Liuran Li et al. Frontiers in Pharmacology
- Impaired ATG16L-Dependent Autophagy Promotes Renal Interstitial Fibrosis in Chronic Renal Graft Dysfunction Through Inducing EndMT by NF-κB Signal Pathway
- (2021) Zeping Gui et al. Frontiers in Immunology
- Canagliflozin attenuates lipotoxicity in cardiomyocytes and protects diabetic mouse hearts by inhibiting the mTOR/HIF-1α pathway
- (2021) Pengbo Sun et al. iScience
- The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin
- (2021) Vincenzo Quagliariello et al. Cardiovascular Diabetology
- SGLT2 Inhibition by Dapagliflozin Attenuates Diabetic Ketoacidosis in Mice with Type-1 Diabetes
- (2021) Huan Chen et al. CARDIOVASCULAR DRUGS AND THERAPY
- SGLT2 inhibitors and the cardiac Na+/H+ exchanger-1: the plot thickens
- (2021) Yu Jin Chung et al. CARDIOVASCULAR RESEARCH
- Effects of empagliflozin on erythropoiesis in patients with type 2 diabetes: Data from a randomized, placebo‐controlled study
- (2021) Kirsten Thiele et al. DIABETES OBESITY & METABOLISM
- Effects of canagliflozin on human myocardial redox signalling: clinical implications
- (2021) Hidekazu Kondo et al. EUROPEAN HEART JOURNAL
- Dapagliflozin attenuates steatosis in livers of high-fat diet-induced mice and oleic acid-treated L02 cells via regulating AMPK/mTOR pathway
- (2021) Jingyi Luo et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Prognostic Importance of NT-proBNP and Effect of Empagliflozin in the EMPEROR-Reduced Trial
- (2021) James L. Januzzi et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Dapagliflozin Restores Impaired Autophagy and Suppresses Inflammation in High Glucose-Treated HK-2 Cells
- (2021) Jing Xu et al. Cells
- AMP-Kinase mediates regulation of glomerular volume and podocyte survival
- (2021) Khadija Banu et al. JCI Insight
- Impact of sodium glucose linked cotransporter‐2 inhibition on renal microvascular oxygen tension in a rodent model of diabetes mellitus
- (2021) Gregory M. T. Hare et al. Physiological Reports
- Dapagliflozin attenuates pressure overload-induced myocardial remodeling in mice via activating SIRT1 and inhibiting endoplasmic reticulum stress
- (2021) Fang-fang Ren et al. ACTA PHARMACOLOGICA SINICA
- Dapagliflozin attenuates arrhythmic vulnerabilities by regulating connexin43 expression via the AMPK pathway in post-infarcted rat hearts
- (2021) Cheng-Che Lee et al. BIOCHEMICAL PHARMACOLOGY
- SGLT-2 inhibitors and cardiorenal outcomes in patients with or without type 2 diabetes: a meta-analysis of 11 CVOTs
- (2021) Dario Giugliano et al. Cardiovascular Diabetology
- Sirt6 protects cardiomyocytes against doxorubicin-induced cardiotoxicity by inhibiting P53/Fas-dependent cell death and augmenting endogenous antioxidant defense mechanisms
- (2021) Sisi Wu et al. CELL BIOLOGY AND TOXICOLOGY
- Dapagliflozin alleviates advanced glycation end product induced podocyte injury through AMPK/mTOR mediated autophagy pathway
- (2021) Lei Yang et al. CELLULAR SIGNALLING
- Enhanced Expression and Function of Renal SGLT2 (Sodium-Glucose Cotransporter 2) in Heart Failure: Role of Renal Nerves
- (2021) Kenichi Katsurada et al. Circulation-Heart Failure
- Empagliflozin Treatment Is Associated With Improvements in Cardiac Energetics and Function and Reductions in Myocardial Cellular Volume in Patients With Type 2 Diabetes
- (2021) Sharmaine Thirunavukarasu et al. DIABETES
- SGLT2 inhibitor counteracts NLRP3 inflammasome via tubular metabolite itaconate in fibrosis kidney
- (2021) Qingqing Ke et al. FASEB JOURNAL
- mTOR-Activating Mutations in RRAGD Are Causative for Kidney Tubulopathy and Cardiomyopathy
- (2021) Karl P. Schlingmann et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- AMPK agonist alleviate renal tubulointerstitial fibrosis via activating mitophagy in high fat and streptozotocin induced diabetic mice
- (2021) Ya-chun Han et al. Cell Death & Disease
- Empagliflozin Induces White Adipocyte Browning and Modulates Mitochondrial Dynamics in KK Cg-Ay/J Mice and Mouse Adipocytes
- (2021) Linxin Xu et al. Frontiers in Physiology
- Sodium-glucose co-transporter2 expression and inflammatory activity in diabetic atherosclerotic plaques: Effects of sodium-glucose co-transporter2 inhibitor treatment
- (2021) Nunzia D'Onofrio et al. Molecular Metabolism
- Ipragliflozin, an SGLT2 Inhibitor, Ameliorates High-Fat Diet-Induced Metabolic Changes by Upregulating Energy Expenditure through Activation of the AMPK/ SIRT1 Pathway
- (2021) Ji-Yeon Lee et al. Diabetes & Metabolism Journal
- Role of Cardiac AMP-Activated Protein Kinase in a Non-pathological Setting: Evidence From Cardiomyocyte-Specific, Inducible AMP-Activated Protein Kinase α1α2-Knockout Mice
- (2021) Malgorzata Tokarska-Schlattner et al. Frontiers in Cell and Developmental Biology
- Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA‐REG OUTCOME trial
- (2021) David Fitchett et al. ESC Heart Failure
- Inhibition of tumor necrosis factor-α enhanced the antifibrotic effect of empagliflozin in an animal model with renal insulin resistance
- (2020) Hoda E. Mohamed et al. MOLECULAR AND CELLULAR BIOCHEMISTRY
- TLR9 and beclin 1 crosstalk regulates muscle AMPK activation in exercise
- (2020) Yang Liu et al. NATURE
- Empagliflozin in Heart Failure: Diuretic and Cardio-Renal Effects
- (2020) Matthew Griffin et al. CIRCULATION
- Role of Deranged Energy Deprivation Signaling in the Pathogenesis of Cardiac and Renal Disease in States of Perceived Nutrient Overabundance
- (2020) Milton Packer CIRCULATION
- Empagliflozin modulates renal sympathetic and heart rate baroreflexes in a rabbit model of diabetes
- (2020) Cindy Gueguen et al. DIABETOLOGIA
- Effects of catheter-based renal denervation on heart failure with reduced ejection fraction: a meta-analysis of randomized controlled trials
- (2020) Hidekatsu Fukuta et al. HEART FAILURE REVIEWS
- SGLT2 Inhibitor Empagliflozin and DPP4 Inhibitor Linagliptin Reactivate Glomerular Autophagy in db/db Mice, a Model of Type 2 Diabetes
- (2020) Anton I. Korbut et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetes
- (2020) JingWei Li et al. KIDNEY INTERNATIONAL
- Canagliflozin ameliorates obesity by improving mitochondrial function and fatty acid oxidation via PPARα in vivo and in vitro
- (2020) Dan Wei et al. LIFE SCIENCES
- Manipulating Sirtuin 3 pathway ameliorates renal damage in experimental diabetes
- (2020) Monica Locatelli et al. Scientific Reports
- SGLT2 Inhibition Mediates Protection from Diabetic Kidney Disease by Promoting Ketone Body-Induced mTORC1 Inhibition
- (2020) Issei Tomita et al. Cell Metabolism
- Chronically Elevating Circulating Ketones Can Reduce Cardiac Inflammation and Blunt the Development of Heart Failure
- (2020) Nikole J. Byrne et al. Circulation-Heart Failure
- Mechanisms of Sodium–Glucose Cotransporter 2 Inhibition: Insights From Large-Scale Proteomics
- (2020) Ele Ferrannini et al. DIABETES CARE
- Sodium Glucose Co-Transporter 2 Inhibitor Ameliorates Autophagic Flux Impairment on Renal Proximal Tubular Cells in Obesity Mice
- (2020) Kazuhiko Fukushima et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Clinical Features and Natural History of PRKAG2 Variant Cardiac Glycogenosis
- (2020) Angela Lopez-Sainz et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Empagliflozin alleviated mitochondrial fission via decreasing PGAM5.
- (2020) Xiangyang Liu et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Empagliflozin protects heart from inflammation and energy depletion via AMPK activation
- (2020) Chintan N. Koyani et al. PHARMACOLOGICAL RESEARCH
- Proximal Tubule mTORC1 Is a Central Player in the Pathophysiology of Diabetic Nephropathy and Its Correction by SGLT2 Inhibitors
- (2020) Aviram Kogot-Levin et al. Cell Reports
- Acute and Chronic Effects of SGLT2 Inhibitor Empagliflozin on Renal Oxygenation and Blood Pressure Control in Nondiabetic Normotensive Subjects: A Randomized, Placebo‐Controlled Trial
- (2020) Anne Zanchi et al. Journal of the American Heart Association
- Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial
- (2020) Wataru Shimizu et al. Cardiovascular Diabetology
- Novel Anti-inflammatory Effects of Canagliflozin Involving Hexokinase II in Lipopolysaccharide-Stimulated Human Coronary Artery Endothelial Cells
- (2020) Laween Uthman et al. CARDIOVASCULAR DRUGS AND THERAPY
- Dietary Carbohydrates Restriction Inhibits The Development Of Cardiac Hypertrophy And Heart Failure
- (2020) Michinari Nakamura et al. CARDIOVASCULAR RESEARCH
- Renal and Cardiovascular Effects of SGLT2 Inhibition in Combination with Loop Diuretics in Patients with Type 2 Diabetes and Chronic Heart Failure: The RECEDE-CHF Trial
- (2020) Natalie A. Mordi et al. CIRCULATION
- Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights from the EMPEROR-Reduced Trial
- (2020) Faiez Zannad et al. CIRCULATION
- Uric Acid Is a Biomarker of Oxidative Stress in the Failing Heart: Lessons Learned from Trials With Allopurinol and SGLT2 Inhibitors
- (2020) Milton Packer JOURNAL OF CARDIAC FAILURE
- Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
- (2020) Milton Packer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Autophagy in Human Diseases
- (2020) Noboru Mizushima et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting Mitochondria-Inflammation Circuit by β-Hydroxybutyrate Mitigates HFpEF
- (2020) Yan Deng et al. CIRCULATION RESEARCH
- Gluconeogenesis, But Not Glycogenolysis, Contributes to the Increase in Endogenous Glucose Production by SGLT-2 Inhibition
- (2020) Peter Wolf et al. DIABETES CARE
- Effects of empagliflozin on renal sodium and glucose handling in patients with acute heart failure
- (2020) Eva M. Boorsma et al. EUROPEAN JOURNAL OF HEART FAILURE
- Effect of Empagliflozin on Hemodynamics in Patients With Heart Failure and Reduced Ejection Fraction
- (2020) Massar Omar et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Targeting Energy Pathways in Kidney Disease: The Roles of Sirtuins, AMPK, and PGC1α
- (2020) Amanda J. Clark et al. KIDNEY INTERNATIONAL
- SIRT3 Deficiency Sensitizes Angiotensin-II-Induced Renal Fibrosis
- (2020) Xiaomeng Feng et al. Cells
- Meta-analysis uncovers genome-wide significant variants for rapid kidney function decline
- (2020) Mathias Gorski et al. KIDNEY INTERNATIONAL
- Biological Functions of Autophagy Genes: A Disease Perspective
- (2019) Beth Levine et al. CELL
- Hyperglycemia-Driven Inhibition of AMP-Activated Protein Kinase α2 Induces Diabetic Cardiomyopathy by Promoting Mitochondria-AssociatedEndoplasmic Reticulum Membranes in vivo
- (2019) Shengnan Wu et al. CIRCULATION
- Novel tubular–glomerular interplay in diabetic kidney disease mediated by sirtuin 1, nicotinamide mononucleotide, and nicotinamide adenine dinucleotide Oshima Award Address 2017
- (2019) Kazuhiro Hasegawa Clinical and Experimental Nephrology
- Cardiovascular Effects of Treatment with the Ketone Body 3-Hydroxybutyrate in Chronic Heart Failure Patients
- (2019) Roni Nielsen et al. CIRCULATION
- AICAR, an AMPK activator, protects against cisplatin-induced acute kidney injury through the JAK/STAT/SOCS pathway
- (2019) Bodokhsuren Tsogbadrakh et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Anti-inflammatory action of β-hydroxybutyrate via modulation of PGC-1α and FoxO1, mimicking calorie restriction
- (2019) Dae Hyun Kim et al. Aging-US
- Phloretin protects against cardiac damage and remodeling via restoring SIRT1 and anti-inflammatory effects in the streptozotocin-induced diabetic mouse model
- (2019) Yin Ying et al. Aging-US
- The cardiomyocyte “redox rheostat”: Redox signalling via the AMPK-mTOR axis and regulation of gene and protein expression balancing survival and death
- (2019) Daniel N. Meijles et al. JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY
- Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics
- (2019) Carlos G. Santos-Gallego et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- β-Hydroxybutyrate, a ketone body, reduces the cytotoxic effect of cisplatin via activation of HDAC5 in human renal cortical epithelial cells
- (2019) Daisuke Mikami et al. LIFE SCIENCES
- Trends in Kidney Function Outcomes Following RAAS Inhibition in Patients With Heart Failure With Reduced Ejection Fraction
- (2019) Wendy McCallum et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Unconventional Secretion Of Adipocyte Fatty Acid Binding Protein 4 Is Mediated By Autophagic Proteins In a Sirtuin-1 Dependent Manner
- (2019) Ajeetha Josephrajan et al. DIABETES
- Possible involvement of normalized Pin1 expression level and AMPK activation in the molecular mechanisms underlying renal protective effects of SGLT2 inhibitors in mice
- (2019) Masa-Ki Inoue et al. Diabetology & Metabolic Syndrome
- Delayed intervention with a novel SGLT2 inhibitor NGI001 suppresses diet‐induced metabolic dysfunction and nonalcoholic fatty liver disease in mice
- (2019) Hao Chiang et al. BRITISH JOURNAL OF PHARMACOLOGY
- Cardiopulmonary Baroreflex Control of Renal Sympathetic Nerve Activity Is Impaired in Dogs With Left Ventricular Dysfunction
- (2019) Mark E. Dunlap et al. JOURNAL OF CARDIAC FAILURE
- Empagliflozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet/streptozotocin-induced diabetic rats
- (2019) Qingmiao Shao et al. Cardiovascular Diabetology
- Effect of Empagliflozin on Erythropoietin Levels, Iron Stores and Red Blood Cell Morphology in Patients with Type 2 Diabetes and Coronary Artery Disease
- (2019) C. David Mazer et al. CIRCULATION
- Rapamycin regulates the balance between�cardiomyocyte apoptosis and autophagy in chronic heart failure by inhibiting mTOR signaling
- (2019) Guangyuan Gao et al. INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
- Inducible Cardiac-Specific Deletion of Sirt1 in Male Mice Reveals Progressive Cardiac Dysfunction and Sensitization of the Heart to Pressure Overload
- (2019) Maria-Nieves Sanz et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial
- (2019) Erik J.M. van Bommel et al. KIDNEY INTERNATIONAL
- Mediators of the Effects of Canagliflozin on Heart Failure in Patients With Type 2 Diabetes
- (2019) JingWei Li et al. JACC-Heart Failure
- Empagliflozin reduces the levels of CD36 and cardiotoxic lipids while improving autophagy in the hearts of Zucker diabetic fatty rats
- (2019) Alana Aragón-Herrera et al. BIOCHEMICAL PHARMACOLOGY
- Dapagliflozin not only improves hepatic injury and pancreatic endoplasmic reticulum stress, but also induces hepatic gluconeogenic enzymes expression in obese rats
- (2019) Myat Theingi Swe et al. CLINICAL SCIENCE
- Effect of dapagliflozin, a sodium‐glucose co‐transporter‐2 inhibitor, on gluconeogenesis in proximal renal tubules
- (2019) Jin Hee Kim et al. DIABETES OBESITY & METABOLISM
- Empagliflozin attenuates ischemia and reperfusion injury through LKB1/AMPK signaling pathway
- (2019) Qingguo Lu et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- The Role of Autophagy in the Heart
- (2018) Sebastiano Sciarretta et al. Annual Review of Physiology
- Canagliflozin exerts anti-inflammatory effects by inhibiting intracellular glucose metabolism and promoting autophagy in immune cells
- (2018) Chenke Xu et al. BIOCHEMICAL PHARMACOLOGY
- Combined SGLT2 and DPP4 Inhibition Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Nephropathy in Mice with Type 2 Diabetes
- (2018) Yochai Birnbaum et al. CARDIOVASCULAR DRUGS AND THERAPY
- Sirtuin 1 activation attenuates cardiac fibrosis in a rodent pressure overload model by modifying Smad2/3 transactivation
- (2018) Antoinette Bugyei-Twum et al. CARDIOVASCULAR RESEARCH
- Heart specific PGC-1α deletion identifies metabolome of cardiac restricted metabolic heart failure
- (2018) Olli Kärkkäinen et al. CARDIOVASCULAR RESEARCH
- A Genome-Wide Association Study of Diabetic Kidney Disease in Subjects With Type 2 Diabetes
- (2018) Natalie R. van Zuydam et al. DIABETES
- Treatment with D-β-hydroxybutyrate protects heart from ischemia/reperfusion injury in mice
- (2018) Yongsheng Yu et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Transient activation of AMPK preceding left ventricular pressure overload reduces adverse remodeling and preserves left ventricular function
- (2018) Deok Hwa Nam et al. FASEB JOURNAL
- CTRP3 protected against doxorubicin-induced cardiac dysfunction, inflammation and cell death via activation of Sirt1
- (2018) Yu-Pei Yuan et al. JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY
- Cinacalcet-mediated activation of the CaMKKβ-LKB1-AMPK pathway attenuates diabetic nephropathy in db/db mice by modulation of apoptosis and autophagy
- (2018) Ji Hee Lim et al. Cell Death & Disease
- High Basolateral Glucose Increases Sodium-Glucose Cotransporter 2 and Reduces Sirtuin-1 in Renal Tubules through Glucose Transporter-2 Detection
- (2018) Hiroyuki Umino et al. Scientific Reports
- Canagliflozin inhibits interleukin-1β-stimulated cytokine and chemokine secretion in vascular endothelial cells by AMP-activated protein kinase-dependent and -independent mechanisms
- (2018) Sarah J. Mancini et al. Scientific Reports
- Empagliflozin rescues diabetic myocardial microvascular injury via AMPK-mediated inhibition of mitochondrial fission
- (2018) Hao Zhou et al. Redox Biology
- Empagliflozin lowers myocardial ketone utilization while preserving glucose utilization in diabetic hypertensive heart disease: A hyperpolarized 13 C magnetic resonance spectroscopy study
- (2018) Desiree Abdurrachim et al. DIABETES OBESITY & METABOLISM
- AMPK/PGC1α activation by melatonin attenuates acute doxorubicin cardiotoxicity via alleviating mitochondrial oxidative damage and apoptosis
- (2018) Dong Liu et al. FREE RADICAL BIOLOGY AND MEDICINE
- Resveratrol ameliorates podocyte damage in diabetic mice via SIRT1/PGC-1α mediated attenuation of mitochondrial oxidative stress
- (2018) Tao Zhang et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Dapagliflozin Attenuates Na+/H+ Exchanger-1 in Cardiofibroblasts via AMPK Activation
- (2018) Yumei Ye et al. CARDIOVASCULAR DRUGS AND THERAPY
- Increased Cardiac Uptake of Ketone Bodies and Free Fatty Acids in Human Heart Failure and Hypertrophic Left Ventricular Remodeling
- (2018) Gabor Voros et al. Circulation-Heart Failure
- Empagliflozin, an SGLT2 inhibitor, reduced the mortality rate after acute myocardial infarction with modification of cardiac metabolomes and anti-oxidants in diabetic rats.
- (2018) Hiroto Oshima et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Renal Denervation Prevents Heart Failure Progression Via Inhibition of the Renin-Angiotensin System
- (2018) Thomas E. Sharp et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Renal Sympathetic Denervation Protects the Failing Heart Via Inhibition of Neprilysin Activity in the Kidney
- (2017) David J. Polhemus et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- mTOR signaling promotes foam cell formation and inhibits foam cell egress through suppressing the SIRT1 signaling pathway
- (2017) Haixiang Zheng et al. Molecular Medicine Reports
- SIRT1 rs10823108 and FOXO1 rs17446614 responsible for genetic susceptibility to diabetic nephropathy
- (2017) Yanyan Zhao et al. Scientific Reports
- SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice
- (2017) Liang Xu et al. EBioMedicine
- Autophagic vacuoles in cardiomyocytes of dilated cardiomyopathy with initially decompensated heart failure predict improved prognosis
- (2016) Tsunenori Saito et al. Autophagy
- Cardiac-Specific Overexpression of miR-222 Induces Heart Failure and Inhibits Autophagy in Mice
- (2016) Ming Su et al. CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
- Shift to Fatty Substrate Utilization in Response to Sodium–Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes
- (2016) Ele Ferrannini et al. DIABETES
- The Na+/Glucose Cotransporter Inhibitor Canagliflozin Activates AMPK by Inhibiting Mitochondrial Function and Increasing Cellular AMP Levels
- (2016) Simon A. Hawley et al. DIABETES
- Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits
- (2016) Antonius Baartscheer et al. DIABETOLOGIA
- Clinical impact of myocardial mTORC1 activation in nonischemic dilated cardiomyopathy
- (2016) Toshiyuki Yano et al. JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY
- Role of the renal sympathetic nerves in renal sodium/potassium handling and renal damage in spontaneously hypertensive rats
- (2016) Jianling Li et al. Experimental and Therapeutic Medicine
- β-Hydroxybutyrate suppresses inflammasome formation by ameliorating endoplasmic reticulum stress via AMPK activation
- (2016) Ha Ram Bae et al. Oncotarget
- SIRT1 and SIRT3 Deacetylate Homologous Substrates: AceCS1,2 and HMGCS1,2
- (2016) Matthew D. Hirschey et al. Aging-US
- Dapagliflozin, SGLT2 Inhibitor, Attenuates Renal Ischemia-Reperfusion Injury
- (2016) Yoon-Kyung Chang et al. PLoS One
- MicroRNA-133a improves the cardiac function and fibrosis through inhibiting Akt in heart failure rats
- (2015) Hai-Qiang Sang et al. BIOMEDICINE & PHARMACOTHERAPY
- AMPK deficiency in cardiac muscle results in dilated cardiomyopathy in the absence of changes in energy metabolism
- (2015) Miranda M. Sung et al. CARDIOVASCULAR RESEARCH
- Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus
- (2015) Ian J Neeland et al. Diabetes & Vascular Disease Research
- Energy Balance After Sodium–Glucose Cotransporter 2 Inhibition
- (2015) Giulia Ferrannini et al. DIABETES CARE
- Crosstalk between the renal sympathetic nerve and intrarenal angiotensin II modulates proximal tubular sodium reabsorption
- (2015) Roberto B. Pontes et al. EXPERIMENTAL PHYSIOLOGY
- Autophagy-Lysosome Pathway in Renal Tubular Epithelial Cells Is Disrupted by Advanced Glycation End Products in Diabetic Nephropathy
- (2015) Wei Jing Liu et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- mTOR regulates MAPKAPK2 translation to control the senescence-associated secretory phenotype
- (2015) Nicolás Herranz et al. NATURE CELL BIOLOGY
- Reduced SIRT1 expression correlates with enhanced oxidative stress in compensated and decompensated heart failure
- (2015) Feridun Akkafa et al. Redox Biology
- In Vivo RNA Interference Models of Inducible and Reversible Sirt1 Knockdown in Kidney Cells
- (2014) Peter Y. Chuang et al. AMERICAN JOURNAL OF PATHOLOGY
- Metabolic Control of Autophagy
- (2014) Lorenzo Galluzzi et al. CELL
- Regulation of Akt Signaling by Sirtuins
- (2014) Vinodkumar B. Pillai et al. CIRCULATION RESEARCH
- Podocyte autophagic activity plays a protective role in renal injury and delays the progression of podocytopathies
- (2014) Caihong Zeng et al. JOURNAL OF PATHOLOGY
- Functional Role of Glucose Metabolism, Osmotic Stress, and Sodium-Glucose Cotransporter Isoform-Mediated Transport on Na+/H+ Exchanger Isoform 3 Activity in the Renal Proximal Tubule
- (2014) T. D. Pessoa et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- The adrenergic regulation of proximal tubular Na+/H+exchanger 3 in the rat
- (2013) V. Healy et al. Acta Physiologica
- AMPK dysregulation promotes diabetes-related reduction of superoxide and mitochondrial function
- (2013) Laura L. Dugan et al. JOURNAL OF CLINICAL INVESTIGATION
- Obesity-Mediated Autophagy Insufficiency Exacerbates Proteinuria-induced Tubulointerstitial Lesions
- (2013) K. Yamahara et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Treatment of Anemia with Darbepoetin Alfa in Systolic Heart Failure
- (2013) Karl Swedberg et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Acetylase/Deacetylase Couple CREB-binding Protein/Sirtuin 1 Controls Hypoxia-inducible Factor 2 Signaling
- (2012) Rui Chen et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Sirtuin Activation: A Role for Plasma Membrane in the Cell Growth Puzzle
- (2012) F. L. Crane et al. JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES
- Effect of Canagliflozin on Renal Threshold for Glucose, Glycemia, and Body Weight in Normal and Diabetic Animal Models
- (2012) Yin Liang et al. PLoS One
- Increased NHE3 abundance and transport activity in renal proximal tubule of rats with heart failure
- (2011) Bruna H. Inoue et al. AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY
- mTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice
- (2011) Ken Inoki et al. JOURNAL OF CLINICAL INVESTIGATION
- Autophagy in immunity and inflammation
- (2011) Beth Levine et al. NATURE
- MTORC1 regulates cardiac function and myocyte survival through 4E-BP1 inhibition in mice
- (2010) Denghong Zhang et al. JOURNAL OF CLINICAL INVESTIGATION
- In vivo stimulation of AMP-activated protein kinase enhanced tubuloglomerular feedback but reduced tubular sodium transport during high dietary NaCl intake
- (2010) Dan Yang Huang et al. PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY
- SIRT1 Negatively Regulates the Mammalian Target of Rapamycin
- (2010) Hiyaa Singhee Ghosh et al. PLoS One
- The mTOR pathway is highly activated in diabetic nephropathy and rapamycin has a strong therapeutic potential
- (2009) Hiroyuki Mori et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity
- (2009) Carles Cantó et al. NATURE
- A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease
- (2009) Marc A. Pfeffer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Activation of Na + /H + Exchanger 1 Is Sufficient to Generate Ca 2+ Signals That Induce Cardiac Hypertrophy and Heart Failure
- (2008) Tomoe Y. Nakamura et al. CIRCULATION RESEARCH
- PGC-1α and ERRα target gene downregulation is a signature of the failing human heart
- (2008) Smita Sihag et al. JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY
- AMPK Phosphorylation of Raptor Mediates a Metabolic Checkpoint
- (2008) Dana M. Gwinn et al. MOLECULAR CELL
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation